Form 4: Organogenesis Holdings Director Transfers Shares to Spouse in Estate Planning Move

A director of Organogenesis Holdings Inc. has transferred over 6 million shares to his spouse as part of an estate planning strategy, maintaining the same overall holdings within a group of controlling stockholders.

Summary

• Alan A. Ades, a director and 10% owner of Organogenesis Holdings Inc., transferred 6,401,945 shares of Class A Common Stock to his spouse, Josette Ades, on January 9, 2025.
• This transfer was a gift for no consideration, made for estate planning purposes.
• The shares were previously directly held by Alan A. Ades and are now held by Josette Ades, both of whom are part of a group of controlling stockholders referred to as the 'Group'.
• The total number of securities held by the Group remains unchanged at 51,085,402 shares.
• The Group, which includes Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom, and their affiliates, has a Controlling Stockholders' Agreement with Organogenesis Holdings Inc., granting them nomination rights for four directors.
• The transfer does not change the Group's beneficial ownership for the purposes of Section 16 of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: The document is neutral, primarily reporting a factual transaction without any positive or negative implications for the company's future. The slight positive sentiment comes from the proactive estate planning, which can be seen as a sign of stability.

Positives

• The transfer indicates proactive estate planning by a key shareholder.
• The overall shareholding of the controlling group remains stable, suggesting continued confidence in the company.
• The Controlling Stockholders' Agreement ensures the group's continued influence on the company's board.

Negatives

• The document does not highlight any negatives.

Risks

• While not explicitly mentioned, a large block of shares held by a controlling group could potentially limit the influence of minority shareholders.
• Changes in the relationships within the controlling group could impact the company's governance.

Future Outlook

The document does not provide any explicit forward-looking statements.

Industry Context

This announcement is specific to Organogenesis Holdings Inc. and does not directly relate to broader industry trends. However, it reflects common practices in corporate governance and estate planning among major shareholders.

Comparison to Industry Standards

• This type of transaction, where a director or major shareholder transfers shares for estate planning purposes, is not uncommon in publicly traded companies.
• For example, similar transactions have occurred in other companies within the healthcare and biotechnology sectors, such as Amgen (AMGN) and Gilead Sciences (GILD), where founders or early investors have transferred shares to trusts or family members.
• The maintenance of a Controlling Stockholders' Agreement is also seen in other companies, such as Facebook (META) with its dual-class share structure, ensuring that certain groups retain significant influence over the company's direction.

Related Party Transactions

• The transfer of shares from Alan A. Ades to his spouse, Josette Ades, is a related party transaction.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on most stakeholders.
• Shareholders' overall ownership structure remains unchanged.
• Employees, customers, suppliers, and creditors are not directly affected by this internal share transfer.

Key Dates

Keywords

Organogenesis Holdings Inc., ORGO, Stock Transfer, Beneficial Ownership, Section 16, Controlling Stockholders' Agreement, Estate Planning, Alan A. Ades, Josette Ades, Securities Exchange Act of 1934